Compare Stocks: IMNM, ARWR, SMMT, and KRYS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$86.34 -0.2%	$83.96	$27.10 ▼ $95.49	$12.16B	1.28	2.28 million shs	757,487 shs
IMNM Immunome	$26.76 -1.5%	$24.83	$8.66 ▼ $30.06	$3.04B	2.13	1.35 million shs	562,127 shs
KRYS Krystal Biotech	$358.24 -3.6%	$350.09	$136.73 ▼ $382.54	$10.60B	0.54	335,590 shs	323,012 shs
SMMT Summit Therapeutics	$17.60 +2.7%	$14.17	$12.07 ▼ $29.23	$14.04B	-1.24	4.25 million shs	6.93 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	+1.31%	-2.37%	-3.46%	+18.33%	+211.12%
IMNM Immunome	-0.62%	-5.92%	+8.38%	+46.18%	+164.98%
KRYS Krystal Biotech	+0.61%	+3.92%	+14.38%	+23.41%	+147.32%
SMMT Summit Therapeutics	+17.33%	+19.54%	+24.49%	+15.98%	-27.17%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$86.34 -0.2%	$83.96	$27.10 ▼ $95.49	$12.16B	1.28	2.28 million shs	757,487 shs
IMNM Immunome	$26.76 -1.5%	$24.83	$8.66 ▼ $30.06	$3.04B	2.13	1.35 million shs	562,127 shs
KRYS Krystal Biotech	$358.24 -3.6%	$350.09	$136.73 ▼ $382.54	$10.60B	0.54	335,590 shs	323,012 shs
SMMT Summit Therapeutics	$17.60 +2.7%	$14.17	$12.07 ▼ $29.23	$14.04B	-1.24	4.25 million shs	6.93 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	+1.31%	-2.37%	-3.46%	+18.33%	+211.12%
IMNM Immunome	-0.62%	-5.92%	+8.38%	+46.18%	+164.98%
KRYS Krystal Biotech	+0.61%	+3.92%	+14.38%	+23.41%	+147.32%
SMMT Summit Therapeutics	+17.33%	+19.54%	+24.49%	+15.98%	-27.17%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.62	Moderate Buy	$98.42	14.20% Upside
IMNM Immunome	2.85	Moderate Buy	$34.64	29.29% Upside
KRYS Krystal Biotech	2.92	Moderate Buy	$365.40	2.13% Upside
SMMT Summit Therapeutics	2.44	Hold	$24.07	39.16% Upside

Current Analyst Ratings Breakdown

Latest IMNM, ARWR, SMMT, and KRYS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/1/2026	SMMT Summit Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/1/2026	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00
8/31/2026	ARWR Arrowhead Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$100.00
8/31/2026	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$115.00
8/26/2026	SMMT Summit Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/26/2026	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/25/2026	SMMT Summit Therapeutics	Summit Redstone Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$11.90
8/25/2026	SMMT Summit Therapeutics	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Underperform ➝ Market Perform	$9.80 ➝ $11.90
8/18/2026	KRYS Krystal Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
8/18/2026	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$829.45M	14.63	$0.12 per share	714.99	$3.31 per share	26.04
IMNM Immunome	$6.94M	438.44	N/A	N/A	$4.62 per share	5.80
KRYS Krystal Biotech	$389.13M	27.22	$7.06 per share	50.65	$45.92 per share	7.79
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	$0.79 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$1.63M	-$2.25	N/A	N/A	N/A	-47.79%	-60.06%	-17.37%	N/A
IMNM Immunome	-$212.39M	-$2.53	N/A	N/A	N/A	N/A	-50.56%	-46.93%	11/5/2026 (Estimated)
KRYS Krystal Biotech	$204.83M	$7.98	44.91	38.35	N/A	54.82%	19.34%	17.65%	11/2/2026 (Estimated)
SMMT Summit Therapeutics	-$1.08B	-$1.12	N/A	N/A	N/A	N/A	-168.94%	-141.92%	10/19/2026 (Estimated)

Latest IMNM, ARWR, SMMT, and KRYS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	IMNM Immunome	-$0.5138	-$0.65	-$0.1362	-$0.65	$0.17 million	N/A
8/4/2026	Q3 2026	ARWR Arrowhead Pharmaceuticals	-$1.23	-$1.36	-$0.13	-$1.36	$44.17 million	$75.25 million
8/3/2026	Q2 2026	KRYS Krystal Biotech	$1.70	$1.79	+$0.09	$1.79	$120.93 million	$119.22 million
7/23/2026	Q2 2026	SMMT Summit Therapeutics	-$0.2744	-$0.28	-$0.0056	-$0.28	$0.11 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	1.77	5.90	5.90
IMNM Immunome	N/A	15.08	15.08
KRYS Krystal Biotech	N/A	8.32	7.96
SMMT Summit Therapeutics	N/A	6.96	6.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
IMNM Immunome	44.58%
KRYS Krystal Biotech	86.29%
SMMT Summit Therapeutics	4.61%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	3.60%
IMNM Immunome	7.21%
KRYS Krystal Biotech	13.10%
SMMT Summit Therapeutics	83.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	140.86 million	135.79 million	Optionable
IMNM Immunome	40	113.58 million	105.39 million	Optionable
KRYS Krystal Biotech	210	29.60 million	25.72 million	Optionable
SMMT Summit Therapeutics	110	797.75 million	131.63 million	Optionable

IMNM, ARWR, SMMT, and KRYS Headlines

Recent News About These Companies

SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China

September 4 at 11:53 AM | zacks.com

Summit Therapeutics: The High Stakes Of Translating China Clinical Data To The U.S.

September 3 at 11:11 PM | seekingalpha.com

Summit packs a punch for Merck's Keytruda — but not everyone is sold

September 3 at 6:11 PM | msn.com

Summit Therapeutics Stock Rises 11%

September 3 at 1:01 PM | rttnews.com

Better cancer therapy than Keytruda? Summit Therapeutics partner's Ivonescimab outperforms in lung cancer study

September 3 at 1:01 PM | msn.com

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up - What's Next?

September 3 at 11:59 AM | marketbeat.com

November 14 Is The Make-Or-Break Moment For Summit Therapeutics' Cancer Bet

September 3 at 7:00 AM | seekingalpha.com

Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China

September 2 at 7:00 PM | businesswire.com

Ten healthcare stocks leading in year-over-year CapEx growth

September 2 at 8:33 AM | msn.com

Summit Therapeutics PLC (NASDAQ:SMMT) Given Consensus Rating of "Hold" by Brokerages

September 2 at 1:59 AM | americanbankingnews.com

Summit Therapeutics (NASDAQ:SMMT) Trading 4.9% Higher - Here's What Happened

September 1 at 3:00 PM | marketbeat.com

The Manufacturers Life Insurance Company Invests $4.34 Million in Summit Therapeutics PLC $SMMT

September 1 at 4:48 AM | marketbeat.com

Hsbc Holdings PLC Invests $1.78 Million in Summit Therapeutics PLC $SMMT

August 31, 2026 | marketbeat.com

Beacon Pointe Advisors LLC Purchases Shares of 98,114 Summit Therapeutics PLC $SMMT

August 31, 2026 | marketbeat.com

Summit Therapeutics Inc.

August 30, 2026 | barrons.com

BlackRock Inc. Invests $138.84 Million in Summit Therapeutics PLC $SMMT

August 29, 2026 | marketbeat.com

Summit Therapeutics PLC (NASDAQ:SMMT) Receives Average Recommendation of "Hold" from Analysts

August 28, 2026 | marketbeat.com

HC Wainwright Reiterates Neutral Rating for Summit Therapeutics (NASDAQ:SMMT)

August 28, 2026 | americanbankingnews.com

SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

August 27, 2026 | zacks.com

Ivonescimab beats Imfinzi in Chinese biliary tract cancer trial

August 27, 2026 | thepharmaletter.comT

Deutsche Bank AG Makes New $3.49 Million Investment in Summit Therapeutics PLC $SMMT

August 27, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNM, ARWR, SMMT, and KRYS Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$86.34 -0.15 (-0.17%)

As of 04:00 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Immunome NASDAQ:IMNM

$26.76 -0.40 (-1.47%)

As of 04:00 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Krystal Biotech NASDAQ:KRYS

$358.24 -13.23 (-3.56%)

As of 04:00 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Summit Therapeutics NASDAQ:SMMT

$17.60 +0.47 (+2.74%)

As of 04:00 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMNM, ARWR, SMMT, and KRYS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMNM, ARWR, SMMT, and KRYS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMNM, ARWR, SMMT, and KRYS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNM, ARWR, SMMT, and KRYS Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

Immunome NASDAQ:IMNM

Krystal Biotech NASDAQ:KRYS

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMNM, ARWR, SMMT, and KRYS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMNM, ARWR, SMMT, and KRYS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMNM, ARWR, SMMT, and KRYS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNM, ARWR, SMMT, and KRYS Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

Immunome NASDAQ:IMNM

Krystal Biotech NASDAQ:KRYS

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools